Non Healing Diabetic Foot Ulcer
Conditions
Brief summary
This is a 12 week, randomized controlled trial. There are 2 arms and 20 patients with non healing diabetic foot ulcer allocated in each arm. One arm receives i:X guided treatment and the other arm receives standard of care treatment. Our primary objective is to compare the wound area reduction in both arms.
Interventions
The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
Sponsors
MolecuLight Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients presenting with chronic DFU * The chronic DFU has a surface area that has reduced \<25% in the previous 4 weeks1 prior to first study visit * Patient has been receiving treatment for their DFU for less than 12 weeks. * The chronic DFU is \> 1 cm2 in area and less than 15 cm in length (max. diameter) * 18 years or older * Willing and able to make all required study visits
Exclusion criteria
* • Patients categorized as having a maintenance wound * Use of skin substitutes or hyperbaric oxygen therapy or surgical intervention * Treatment with an investigational drug within 1 month of enrolment * Presents with chronic (\>10 mg/kg for \>30 days) systemic corticoids before enrolment * Has ABI \<0.5 (measured within 3 months of randomisation) * Undergoing chemotherapy or is immunocompromised * Diagnosed with Charcot disease or ulcers from electrical, chemical or radiation burns, or presents with collagen vascular disease, ulcer malignancy, untreated osteomyelitis or cellulitis * Recombinant or autologous growth factors or skin/dermal substitutes within 30 days of enrollment * Inability or unwillingness to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of change in wound area of diabetic foot ulcers in ARM 2 vs ARM 1 | 5 months | ARM 2 vs ARM 1 Evaluate change in wound area over 12-week period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Wound Healing Rate | 5 months | ARM 1 vs. ARM 2 1. Evaluate increase in wound healing rate over 12-week period 2. Evaluate differences in clinical infection i. time to eradicate an infection ii. incidence of new infection (i.e. infection avoidance) 3. Determine if MolecuLight i:X images taken at baseline can predict non-healing wounds, region for debridement and/or wounds at risk of infection (based on fluorescent signatures) at 6 and 12 weeks. |
Countries
United States
Outcome results
None listed